SEP-4199

**SEP-4199** is an investigational, orally administered non-racemic amisulpride product consisting of aramisulpride and esamisulpride in an 85:15 ratio. It was developed by Sunovion and Sumitomo Pharma for major depressive episodes associated with bipolar I disorder. The enantiomer ratio was designed to favor serotonin 5-HT7 receptor antagonism associated with aramisulpride while reducing dopamine D2 receptor antagonism associated with esamisulpride, with the goal of preserving antidepressant and antipsychotic-relevant activity while limiting D2-related extrapyramidal risk. A Phase 2 study was completed, while Phase 3 controlled-release studies were terminated; Sumitomo Pharma subsequently listed SEP-4199 among internal products whose development had been discontinued. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8453756/))

Other names

non-racemic amisulpridearamisulpride + esamisulpride